Alzinova announces biomarker collaboration with Sahlgrenska University Hospital
GU Ventures sprider nyheter och information kring verksamheten, sina bolag, samt alumnibolag.
Nyhetens sammanfattning på svenska:
Alzinova samarbetar med framstående forskare vid Sahlgrenska universitetssjukhuset i Göteborg för att spåra markörer för neurodegenerativ förändring av Alzheimers sjukdom.
Resterande pressmeddelande följer på engelska:
Alzinova is collaborating with prominent researchers at Sahlgrenska University Hospital in Gothenburg, Sweden, to track markers of neurodegenerative change in Alzheimer’s disease.
As part of the ongoing preparations for its upcoming Phase 1b clinical study with therapeutic vaccine (ALZ-101) for the treatment of Alzheimer’s disease, Alzinova has initiated a collaboration with the Clinical Neurochemistry Laboratory at Sahlgrenska University Hospital. The work will be led by Kaj Blennow and Henrik Zetterberg, world-leading professors in neurochemistry.
The collaboration will focus on measuring and evaluating potential changes in biomarkers associated with Alzheimer’s disease and/or neurodegeneration following multiple immunisations with ALZ-101, as compared to placebo, in study participants with early Alzheimer’s disease.
More specifically, the research will measure:
- Changes in cerebrospinal fluid (CSF) concentrations of amyloid Aβ42, Aβ40, Aβ42/40 ratio, T-tau and P-tau.
- Changes in blood (plasma) and CSF concentrations of NFL.
- Changes in CSF of concentrations of neurogranin, TREM-2 and YKL-40; and possibly other biomarkers related to Alzheimer’s disease and/or neurodegeneration.
Kristina Torfgård, CEO at Alzinova, says, “We are very pleased to be collaborating with Henrik Zetterberg, Kaj Blennow and the distinguished Clinical Neurochemistry Laboratory at Sahlgrenska University Hospital. The highly respected and highly cited work Henrik and Kaj are doing is helping to advance the development of biomarkers for neurodegenerative diseases. Such markers are key to furthering our understanding of Alzheimer’s disease diagnosis and progression.”
About Alzinova AB
Alzinova AB is a Swedish biopharma company specializing in the treatment of Alzheimer’s disease by targeting neurotoxic amyloid-β oligomers. The lead candidate, ALZ-101, is in late preclinical development as a therapeutic vaccine for the treatment of Alzheimer's. Alzinova’s proprietary AβCC peptide™ technology enables the development of disease-modifying therapies that target the toxic amyloid-β oligomers involved in the onset and progression of the disease with high precision. Alzheimer’s is one of the most common and devastating neurological diseases globally, with of the order of 40 million people afflicted today. In addition, the antibody ALZ-201, in early preclinical development, was generated with the AβCC peptide™ technology and the ambition is to expand the pipeline further. The Company’s Certified Advisor on Nasdaq First North is Corpura Fondkommission AB, email@example.com, +46 (0)768-532 822. For more information about Alzinova, please visit: www.alzinova.com
About GU Ventures AB
GU Ventures builds businesses out of groundbreaking ideas that help shape a better tomorrow and is top-ranked by UBI Global Index as one of the world's 20 leading university-run incubators. We finance and develop new innovative business ideas with connections to the University of Gothenburg, which is one of northern Europe's largest universities. Our mission is commercialize the innovations, which leads to the utilization of research and skills, renewal of the business community, job creation and sustainable growth. Our passionate team of company builders, financial experts, IP and legal talent are dedicated supporters of our companies and ensure their successes. Since our starting point in 1995, GU Ventures has developed over 200 new business ideas of which 130 are in business today and of which 14 are listed. Our portfolio consists of 70 holdings and some projects. In the latest survey, 87% of companies match the global sustainability goals set by the UN. GU Ventures is wholly owned by the Swedish state and managed by the University of Gothenburg. Feel free to read more at: www.guventures.com.